REPLIGEN CORP acquired 908 Devices Inc. bioprocessing PAT Portfolio for ~$70.3 million total consideration, a transaction completed in March 2025, structured as all cash.
908 Devices Inc. bioprocessing PAT Portfolio operates in Process Analytics, is based in North Carolina, USA and Braunschweig, Germany. Acquisition of 908 Devices Inc.'s desktop portfolio of four bioprocessing process analytical technology (PAT) devices, together with related facilities, employees, equipment and lease obligations in North Carolina and Braunschweig, Germany. The deal added upstream PAT solutions, complementing the downstream PAT capability gained from C Technologies in 2019, and was rebranded under the PATsmart line in 2025.
Per Repligen's 10-K, the addition of these desktop assets complements and strengthens Repligen's Analytics portfolio, adding upstream PAT to its existing downstream PAT offering.
Upstream PAT capability complementing downstream Slope Spectroscopy. Completes the PAT franchise (upstream + downstream) under PATsmart. Repligen Process Analytics (PATsmart)
We added to our Analytics portfolio in 2025 through the acquisition of 908 Devices Inc.'s bioprocessing portfolio, which brought upstream PAT solutions. In 2025, we rebranded our Analytics offerings to PATsmart.Repligen FY25 10-K, Item 1 Business
Advisory firms were not disclosed for this transaction.